Adenocarcinoma in Situ disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

Sources

Aliases & Classifications for Adenocarcinoma in Situ

MalaCards integrated aliases for Adenocarcinoma in Situ:

Name: Adenocarcinoma in Situ ¹¹ ⁴³ ¹⁴ ⁷¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:4943

MeSH ⁴³ D065311

NCIt ⁴⁹ C4123

SNOMED-CT ⁶⁸ 51642000

UMLS ⁷¹ C0334276

Sources

Summaries for Adenocarcinoma in Situ

Disease Ontology: ¹¹ An in situ carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary: Adenocarcinoma in Situ is related to early invasive cervical adenocarcinoma and pulmonary adenocarcinoma in situ. An important gene associated with Adenocarcinoma in Situ is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Malignant pleural mesothelioma and Endometrial cancer. The drugs Vaccines and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include cervix, lung and prostate, and related phenotypes are Decreased viability and homeostasis/metabolism

Sources

Related Diseases for Adenocarcinoma in Situ

Diseases in the Adenocarcinoma family:

Adenocarcinoma in Situ

Diseases related to Adenocarcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 548)

#	Related Disease	Score	Top Affiliating Genes
1	early invasive cervical adenocarcinoma	32.3	INSM1 CDKN2A
2	pulmonary adenocarcinoma in situ	31.5	TP53 NKX2-1 KRT7 KRAS HRAS EGFR
3	cervical adenocarcinoma	30.5	TP53 MAPK8IP1 KRT7 KRAS INSM1 CEACAM5
4	cervix endometriosis	30.5	MAPK8IP1 CDKN2A
5	endometrial mucinous adenocarcinoma	30.4	KRAS CDKN2A
6	appendix adenocarcinoma	30.1	TP53 KRT7 KRAS HRAS CEACAM5
7	adenocarcinoma	30.1	TP53 NKX2-1 NAPSA KRT7 KRAS HRAS
8	cervical polyp	30.1	MUC6 MAPK8IP1
9	endometrial hyperplasia	30.0	TP53 KRAS CDKN2A
10	exanthem	30.0	KRAS HRAS EGFR ALK
11	barrett esophagus	30.0	TP53 MUC6 KRT7 CDKN2A
12	cystadenoma	30.0	MUC6 KRT7 CEACAM5
13	suppressor of tumorigenicity 3	30.0	TP53 CDKN2A
14	papilloma	29.9	TP53 KRT7 KRAS EGFR CDKN2A
15	endometrial adenocarcinoma	29.9	TP53 KRT7 KRAS EGFR CDKN2A
16	esophagus adenocarcinoma	29.9	TP53 EGFR CDKN2A
17	adenoma	29.8	TP53 MUC6 KRT7 KRAS HRAS CDKN2A
18	endocervical adenocarcinoma	29.7	U2AF1 TP53 MUC6 MAPK8IP1 KRT7 INSM1
19	duodenum adenocarcinoma	29.7	MUC6 KRT7 KRAS HRAS CEACAM5
20	clear cell adenocarcinoma	29.6	TP53 NAPSA KRT7
21	cervical squamous cell carcinoma	29.6	TP53 KRAS EGFR CEACAM5 CDKN2A
22	cystic teratoma	29.6	TP53 NKX2-1 KRT7 CEACAM5
23	benign teratoma	29.5	TP53 NKX2-1 KRT7 CEACAM5
24	gastric adenocarcinoma	29.5	TP53 KRAS HRAS CEACAM5 CDKN2A
25	papillary adenocarcinoma	29.5	TP53 NKX2-1 NAPSA KRT7 KRAS HRAS
26	ovarian mucinous neoplasm	29.5	U2AF1 MUC6 KRT7 KRAS HRAS CEACAM5
27	ductal carcinoma in situ	29.5	TP53 PDPN EGFR CDKN2A
28	endometrial cancer	29.5	TP53 KRT7 KRAS HRAS EGFR CEACAM5
29	colon adenocarcinoma	29.5	TP53 KRAS HRAS EGFR CEACAM5
30	peritoneum cancer	29.5	TP53 KRT7 EGFR CEACAM5 CDKN2A
31	cervix uteri carcinoma in situ	29.5	TP53 PTPRN MAPK8IP1 INSM1 GP5 CDKN2A
32	bronchiolo-alveolar adenocarcinoma	29.4	TP53 NKX2-1 MUC6 KRT7 KRAS HRAS
33	lung cancer susceptibility 3	29.4	U2AF1 TP53 NKX2-1 NAPSA KRT7 KRAS
34	pseudomyxoma peritonei	29.4	TP53 MUC6 KRT7 KRAS CEACAM5
35	cholangiocarcinoma	29.3	TP53 KRT7 KRAS EGFR CEACAM5 CDKN2A
36	teratoma	29.3	TP53 NKX2-1 KRT7 KRAS CEACAM5 CDKN2A
37	colorectal adenocarcinoma	29.3	TP53 KRT7 KRAS HRAS EGFR CEACAM5
38	villous adenoma	29.2	TP53 MUC6 KRT7 KRAS HRAS CEACAM5
39	serous cystadenocarcinoma	29.2	TP53 NAPSA KRT7 KRAS HRAS CDKN2A
40	gallbladder adenocarcinoma	29.2	TP53 PDPN MUC6 KRT7 HRAS CEACAM5
41	lung benign neoplasm	29.1	TP53 NKX2-1 KRT7 KRAS HRAS EGFR
42	squamous cell carcinoma	29.1	TP53 PDPN NKX2-1 KRT7 KRAS HRAS
43	ovary adenocarcinoma	29.0	U2AF1 TP53 KRT7 KRAS HRAS EGFR
44	hemangioma	28.9	TP53 PDPN NKX2-1 KRT7 KRAS EGFR
45	gallbladder disease	28.9	TP53 PDPN KRT7 KRAS HRAS EGFR
46	adenosquamous carcinoma	28.9	PTPRN NKX2-1 MAPK8IP1 KRT7 KRAS INSM1
47	large cell neuroendocrine carcinoma	28.6	TP53 NKX2-1 NAPSA KRT7 KRAS INSM1
48	mucinous adenocarcinoma	28.6	U2AF1 TP53 NKX2-1 NAPSA MUC6 KRT7
49	gallbladder cancer	28.5	TP53 PDPN MUC6 KRT7 KRAS HRAS
50	cervical intraepithelial neoplasia	10.5

Graphical network of the top 20 diseases related to Adenocarcinoma in Situ:

Sources

Symptoms & Phenotypes for Adenocarcinoma in Situ

GenomeRNAi Phenotypes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

²⁵ (show all 11)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	9.68	EGFR HRAS KRAS
2	Decreased viability	GR00055-A-2	9.68	EGFR HRAS KRAS
3	Decreased viability	GR00055-A-3	9.68	KRAS
4	Decreased viability	GR00106-A-0	9.68	KRAS
5	Decreased viability	GR00221-A-1	9.68	ALK CDKN2A EGFR HRAS KRAS
6	Decreased viability	GR00221-A-2	9.68	HRAS KRAS
7	Decreased viability	GR00221-A-3	9.68	CDKN2A HRAS
8	Decreased viability	GR00221-A-4	9.68	ALK CDKN2A EGFR
9	Decreased viability	GR00249-S	9.68	ALK
10	Decreased viability	GR00301-A	9.68	KRAS
11	Decreased viability	GR00381-A-1	9.68	KRAS

MGI Mouse Phenotypes related to Adenocarcinoma in Situ:

⁴⁵ (show all 11)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.36	ALK CDKN2A CEACAM5 CLDN1 CLDN10 EGFR
2	growth/size/body region	MP:0005378	10.18	ALK CDKN2A CEACAM5 CLDN1 EGFR HRAS
3	neoplasm	MP:0002006	10.13	ALK CDKN2A CEACAM5 EGFR HRAS KRAS
4	endocrine/exocrine gland	MP:0005379	10.1	ALK CDKN2A CEACAM5 EGFR HRAS INSM1
5	no phenotypic analysis	MP:0003012	10.06	CDKN2A EGFR HRAS INSM1 KRAS NKX2-1
6	muscle	MP:0005369	10.03	CDKN2A CEACAM5 EGFR HRAS KRAS PDPN
7	pigmentation	MP:0001186	9.97	ALK CDKN2A EGFR KRAS TP53 U2AF1
8	digestive/alimentary	MP:0005381	9.96	CDKN2A CEACAM5 EGFR HRAS INSM1 KRAS
9	respiratory system	MP:0005388	9.81	ALK CDKN2A EGFR HRAS INSM1 KRAS
10	mortality/aging	MP:0010768	9.8	ALK CDKN2A CEACAM5 CLDN1 EGFR HRAS
11	integument	MP:0010771	9.28	ALK CDKN2A CLDN1 EGFR HRAS KRAS

Sources

Drugs & Therapeutics for Adenocarcinoma in Situ

Drugs for Adenocarcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 18)

#

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Vaccines

Phase 4

2

Immunologic Factors

Phase 3

3

Cyclophosphamide

Approved, Investigational

Phase 1, Phase 2

50-18-0, 6055-19-2

2907

4

Testosterone

Approved, Investigational

Phase 1, Phase 2

58-22-0

5408 6013

Synonyms:

(+-)-8-ISO-TESTOSTERONE

(+-)-RETROTESTOSTERONE

(+)-TESTOSTERONE

(+-)-TESTOSTERONE

(17B)-17-HYDROXY-ANDROST-4-EN-3-ONE

(1S,2R,10R,11S,14S,15S)-14-HYDROXY-2,15-DIMETHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADEC-6-EN-5-ONE

13-ISO-TESTOSTERONE

17 beta Hydroxy 4 androsten 3 one

17 beta Hydroxy 8 alpha 4 androsten 3 one

17A-HYDROXY-(13A)-ANDROST-4-EN-3-ONE

17A-HYDROXY-13A-ANDROST-4-EN-3-ONE

17A-HYDROXY-14B-ANDROST-4-EN-3-ONE

17A-HYDROXY-ANDROST-4-EN-3-ONE

17-beta-Hydroxy-4-androsten-3-one

17BETA-HYDROXY-4-ANDROSTEN-3-ONE

17-beta-Hydroxy-8 alpha-4-androsten-3-one

17B-HYDROXY-(10A)-ANDROST-4-EN-3-ONE

17B-HYDROXY-(13A)-ANDROST-4-EN-3-ONE

17B-HYDROXY-(8A)-ANDROST-4-EN-3-ONE

17B-HYDROXY-(8A,10A)-ANDROST-4-EN-3-ONE

17B-HYDROXY-(9B)-ANDROST-4-EN-3-ONE

17B-HYDROXY-(9B,10A)-ANDROST-4-EN-3-ONE

17B-HYDROXY-13A-ANDROST-4-EN-3-ONE

17b-Hydroxy-4-androsten-3-one

17B-HYDROXY-8A-ANDROST-4-EN-3-ONE

17B-HYDROXY-ANDROST-4-EN-3-ON

17B-HYDROXYANDROST-4-EN-3-ONE

17B-HYDROXY-ANDROST-4-EN-3-ONE

17B-HYDROXYANDROST-4-ENE-3-ONE

17B-HYDROXY-D4-ANDROSTEN-3-ONE

17B-TESTOSTERONE

17-HYDROXY-10,13-DIMETHYL-1,2,6,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE

17-HYDROXY-ANDROST-4-EN-3-ONE

17-HYDROXY-D4-ANDROSTEN-3-ONE

17Β-hydroxy-4-androsten-3-one

4-ANDROSTEN-17BETA-OL-3-ONE

4-Androsten-17b-ol-3-one

4-ANDROSTEN-17Β-OL-3-ONE

4-ANDROSTEN-3-ONE-17B-OL

8 Isotestosterone

8-Isotestosterone

8-ISO-TESTOSTERONE

9B,10A-TESTOSTERONE

9B-TESTOSTERONE

Andriol

Andro

Andro 100

Andro L.A. 200

ANDRODERM

Androderm®|Delatestryl®

ANDROGEL

ANDROGEL 1%

Android 10

Android 25

Android 5

Androlin

Andronaq

Andronate 100

Andronate 200

ANDROPATCH

Andropository 200

Androsorb

ANDROST-4-EN-17B-OL-3-ONE

ANDROST-4-ENE-17B-OL-3-ONE

Androtop

Andrusol

Andryl 200

AstraZeneca brand OF testosterone

Auxilium pharmaceuticals inc. brand OF testosterone

AXIRON

Bartor brand OF testosterone

Beta Testosterone

Bio-T-Gel

CDB 111C

CEPA brand OF testosterone

Cristerona T

Cristerone T

D4-ANDROSTEN-17B-OL-3-ONE

Dea No. 4000

Delatest

DELATESTRYL

Depotest

Depo-Testosterone

Depo-Testosterone Cypionate

Dr. kade brand OF testosterone

Epitestosteron

Everone 200

Faulding brand OF testosterone

Ferring brand OF testosterone

FORTESTA

Geno-cristaux gremy

GlaxoSmithKline brand OF testosterone

Hauck brand OF testosterone

Histerone

Homosteron

Homosterone

INTRINSA

Libigel

LUMITESTOSTERON

Malerone

Malestrone

Malogen in Oil

Malogen, Aquaspension Injection

MERTESTATE

Metandren

Methyltestosterone

NATESTO

Neo-Hombreol F

Neotestis

Neo-Testis

NSC-9700

Oreton

Oreton F

Oreton Methyl

Oreton-F

Orquisteron

Ortho brand OF testosterone

Paladin brand OF testosterone

Pasadena brand OF testosterone

Perandren

Percutacrine androgenique

Primotest

Primoteston

RAC-17B-HYDROXY-(13A)ANDROST-4-EN-3-ONE

RAC-17B-HYDROXY-(8A)-ANDROST-4-EN-3-ONE

RAC-17B-HYDROXY-(9B,10A)ANDROST-4-EN-3-ONE

RAC-17B-HYDROXY-ANDROST-4-EN-3-ONE

Relibra

RETROTESTOSTERONE

Scheinpharm Testone-Cyp

Schering brand OF testosterone

SmithKline beecham brand OF testosterone

Solvay brand OF testosterone

Sterotate

STRIANT

STRIANT SR

Sustanon

Sustanone

Sustason 250

Synandrol F

T-Cypionate

TES

Teslen

Testamone 100

Testandrone

Testaqua

Testiculosterone

TESTIM

TESTIM 1%

Testobase

TESTODERM

TESTODERM TTS

TESTOGEL

Testoject-50

Testolent

Testolin

TESTOPATCH

TESTOPEL

Testopel Pellets

Testopropon

TESTORAL

Testosteroid

TESTOSTERON

TESTOSTERONA

Testosterona [INN-Spanish]

TESTOSTERONE

TESTOSTÉRONE

TESTOSTERONE CIII

Testosterone Cypionate

Testosterone Enanthate

Testosterone Hydrate

Testosterone sulfate

TESTOSTERONUM

Testosteronum [INN-Latin]

Testostosterone

Testoviron

Testoviron schering

Testoviron T

Testred

Testred Cypionate 200

Testrin-P.A

Testro aq

TESTRONE

Testryl

TOSTRAN

Tostrelle

Tostrex

Trans-Testosterone

Ulmer brand OF testosterone

Unimed brand OF testosterone

Viatrel

Virilon

Virilon IM

Virormone

VIROSTERONE

VOGELXO

Watson brand OF testosterone

5

Sargramostim

Approved, Investigational

Phase 1, Phase 2

123774-72-1

6

Metformin

Approved

Phase 2

1115-70-4, 657-24-9

4091

7

Molgramostim

Investigational

Phase 1, Phase 2

99283-10-0

8

Alkylating Agents

Phase 1, Phase 2

9

Antirheumatic Agents

Phase 1, Phase 2

10

Antineoplastic Agents, Alkylating

Phase 1, Phase 2

11

Hormones

Phase 1, Phase 2

12

Androgens

Phase 1, Phase 2

13

Immunosuppressive Agents

Phase 1, Phase 2

14

Hypoglycemic Agents

Phase 2

15

Proflavine

Approved

92-62-6

7099

16

Anti-Infective Agents

17

Pharmaceutical Solutions

18

Anti-Infective Agents, Local

Interventional clinical trials:

(show all 14)

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women	Completed	NCT01544478	Phase 4
2	Comparison of Video-assisted Thoracoscopic Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion	Unknown status	NCT02011997	Phase 3
3	A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam	Completed	NCT03546842	Phase 3
4	A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica.	Completed	NCT00128661	Phase 3
5	A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years	Active, not recruiting	NCT03493542	Phase 3
6	A Neoadjuvant Immunologic Study of Androgen Deprivation Therapy Combined With a Granulocytemacrophage-colony Stimulating Factor F-secreting Allogeneic Prostate Cancer Vaccine and Low-dose Cyclophosphamide in Men With High-risk Localized Prostate Cancer Undergoing Radical Prostatectomy	Completed	NCT01696877	Phase 1, Phase 2	degarelix acetate;Cyclophosphamide;GVAX
7	Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer: An Internal Pilot Study	Completed	NCT03053544	Phase 2	Metformin
8	Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix	Completed	NCT02206048		Proflavine
9	Prevalence of Anal Dysplasia and Anal Cancer in Women With Cervical, Vaginal and Vulvar Dysplasia and Cancer	Recruiting	NCT02140021
10	Clinical Evaluation Study of Urine hrHPV Detection for the Diagnosis of Presence of Cervical HPV and Correlation of Cervical Lesions	Recruiting	NCT05210348
11	CT-based Radiomic Algorithm for Assisting Surgery Decision and Predicting Immunotherapy Response of NSCLC	Recruiting	NCT04452058
12	HSIL/ACIS/Early Cervical Cancer: What Are The Current Causative HPV Subtypes in the Era of HPV Vaccination?	Recruiting	NCT02937155
13	Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women - A Randomized Trial	Enrolling by invitation	NCT04755517
14	Primary Cervical Cancer Screening by Self-sampling HPV Test	Not yet recruiting	NCT05613283

Search NIH Clinical Center for Adenocarcinoma in Situ

Cochrane evidence based reviews: adenocarcinoma in situ

Sources

Genetic Tests for Adenocarcinoma in Situ

Sources

Anatomical Context for Adenocarcinoma in Situ

Organs/tissues related to Adenocarcinoma in Situ:

MalaCards : Cervix, Lung, Prostate, Lymph Node, Smooth Muscle, Colon, Pancreas

Sources

Publications for Adenocarcinoma in Situ

Articles related to Adenocarcinoma in Situ:

(show top 50) (show all 1489)

#	Title	Authors	PMID	Year
1	HPV type-specific trends in cervical precancers in the United States, 2008 to 2016. ⁶²	Gargano JW...HPV-IMPACT Working Group	35904861	2023
2	Older women testing positive for HPV 16/18 on cervical screening and risk of high-grade cervical abnormality. ⁶²	Roberts JM...Farnsworth A	36468183	2022
3	Adenocarcinoma in situ or early-stage cervical cancer is a risk factor for preterm delivery after cervical conization: a multicenter observational study. ⁶²	Kasuga Y...Aoki D	35341455	2022
4	Ten-year follow-up of lung cancer patients with resected adenocarcinoma in situ or minimally invasive adenocarcinoma: Wedge resection is curative. ⁶²	Li D...Chen H	35965138	2022
5	Evolution of lung adenocarcinoma from preneoplasia to invasive adenocarcinoma. ⁶²	Zhu J...Jiang T	36325966	2022
6	Delineating the dynamic evolution from preneoplasia to invasive lung adenocarcinoma by integrating single-cell RNA sequencing and spatial transcriptomics. ⁶²	Zhu J...Jiang T	36434043	2022
7	Comparison of the safety between cervical conization and hysterectomy for patients with cervical adenocarcinoma in situ. ⁶²	Liu J...Shen Y	36424703	2022
8	Use of a radiofrequency identification system for precise sublobar resection of small lung cancers. ⁶²	Ueda Y...Sato T	36401101	2022
9	Uniportal video-assisted thoracic surgery basal segmentectomy: a single-center retrospective cohort study. ⁶²	Tang Y...Liu L	36386453	2022
10	Conservative Treatment for Cervical Adenocarcinoma In Situ: Long-Term Results. ⁶²	Monti E...Liverani CA	35917498	2022
11	Predictors of treatment failure for adenocarcinoma in situ of the uterine cervix: Up to 14 years of recorded follow-up. ⁶²	Belkic K...Megyessi D	36168314	2022
12	Benign stratified intraepithelial mucinous proliferation of the uterine cervix: Significance of a previously unreported potential mimic of SMILE. ⁶²	Arslanian E...Quddus MR	35988376	2022
13	Diagnostic utility of ThinPrep Imaging System® for detecting atypical glandular cells in cervical smear samples. ⁶²	Akca Y...Erkilic S	36308412	2022
14	HPV-genotyping versus conventional cervical cytology as a screening method to detect dysplastic cervical epithelial changes. ⁶²	Abbas M...Bettendorf O	36280748	2022
15	Incidence of cervical precancerous lesions and cervical cancer in Denmark from 2000 to 2019: Population impact of multi-cohort vaccination against human papillomavirus infection. ⁶²	Ring LL...Kjaer SK	36250312	2022
16	Structure-based classification of EGFR mutations in operable pre-invasive and invasive non-small cell lung cancer: a cross-sectional study. ⁶²	Wang T...Chen R	36245625	2022
17	α-cyanoacrylate rapid medical adhesive (medical EC glue) localization of pulmonary nodules guided by computed tomography before thoracoscopic surgery. ⁶²	Liu Y...Han Y	36125820	2022
18	Association between quantitative spectral CT parameters, Ki-67 expression, and invasiveness in lung adenocarcinoma manifesting as ground-glass nodules. ⁶²	Wu N...Deng K	36131377	2022
19	Corrigendum to "False-Negative Pap Tests in Women with Biopsy-Proven Invasive Endocervical Adenocarcinoma/Adenocarcinoma In Situ: A Retrospective Analysis with Assessment of Inter-Observer Agreement" Journal of the American Society of Cytopathology 2021;11:3-12. ⁶²	Lin M...Okoye E	36114101	2022
20	Endocervical Adenocarcinoma: Comprehensive Histological Review and Re-classification of 123 Consecutive Cases According to the Updated World Health Organization Classification of Female Genital Tumors. ⁶²	Lee Y...Kim HS	36039458	2022
21	Cytopathologic features of human papillomavirus-independent, gastric-type endocervical adenocarcinoma. ⁶²	Yeo MK...Suh KS	36128862	2022
22	Low-grade Neuroendocrine Tumor of the Cervix: Report of 3 Cases of a Rare Neoplasm With Review of the Literature. ⁶²	Sah S...McCluggage WG	35075048	2022
23	A Nomogram Incorporating Tumor-Related Vessels for Differentiating Adenocarcinoma In Situ from Minimally Invasive and Invasive Adenocarcinoma Appearing as Subsolid Nodules. ⁶²	Deng L...Xue LM	36150965	2022
24	The value of the endocervical margin status in LEEP: analysis of 610 cases. ⁶²	Mirandez CC...Vale DB	35220477	2022
25	Investigation on the incidence and risk factors of lung cancer among Chinese hospital employees. ⁶²	Chen ZH...Nie Q	35818719	2022
26	Quantitative CT imaging analysis to predict pathology features in patients with a congenital pulmonary airway malformation. ⁶²	Hermelijn SM...Schnater JM	34809963	2022
27	The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010. ⁶²	Ito H...Japanese Joint Committee of Lung Cancer Registry	35948946	2022
28	Computed Tomography Findings for Predicting Invasiveness of Lung Adenocarcinomas Manifesting as Pure Ground-Glass Nodules. ⁶²	Park J...Chang S	35840350	2022
29	A triple-classification for the evaluation of lung nodules manifesting as pure ground-glass sign: a CT-based radiomic analysis. ⁶²	Yu Z...Ji F	35896975	2022
30	[Development and task of gynecologic pathology]. ⁶²	Zhou XR	35785827	2022
31	Cervical adenocarcinoma in situ during pregnancy and subsequent fertility-sparing therapy challenge. ⁶²	Sanchez-Cuerda C...Cabrera Y	34559882	2022
32	Predictors of Invasiveness in Adenocarcinoma of Lung with Lepidic Growth Pattern. ⁶²	Young TJ...Barjaktarevic I	35893116	2022
33	Correlation of computed tomography quantitative parameters with tumor invasion and Ki-67 expression in early lung adenocarcinoma. ⁶²	Dong H...Qiu Y	35758369	2022
34	[Global guidelines for cervical cancer and precancerous lesions treatment: a systematic review]. ⁶²	Zhao S...Zhao FH	35692019	2022
35	Minimally Invasive and Sublobar Resections for Lung Cancer. ⁶²	Godfrey CM...Grogan EL	35671768	2022
36	Application of Mimics Medical 21.0 Software in thoracoscopic anatomical sublobectomy. ⁶²	You YH...Lu JZ	34160177	2022
37	The Effect of Surgeon Volume on the Outcome of Laser Vaporization: A Single-Center Retrospective Study. ⁶²	Maeda M...Kamiura S	35621692	2022
38	Indeterminate pulmonary subsolid nodules in patients with no history of cancer: growing prediction, CT pattern, and pathological diagnosis. ⁶²	Guo X...Shi G	35748205	2022
39	Performance of three colposcopic images for the identification of squamous and glandular cervical precursor neoplasias. ⁶²	Fachetti-Machado G...Moreira MAR	34727221	2022
40	Preventing Uterine Cervix Cancer: The Clinical Meaning of Atypical Glandular Cells. ⁶²	Almeida G...Furtado Y	35139566	2022
41	Development and validation of qualitative and quantitative models to predict invasiveness of lung adenocarcinomas manifesting as pure ground-glass nodules based on low-dose computed tomography during lung cancer screening. ⁶²	Liu J...Zhou P	35502397	2022
42	PTEN Loss and ARID1A Mutation in an HPV-positive Metastatic Adenocarcinoma Diagnosed Almost 18 yr After an Intact Cone Excision for Endocervical Adenocarcinoma In Situ. ⁶²	Aisagbonhi O...Fadare O	34282106	2022
43	Endocervical adenocarcinoma in situ with ovarian metastases. ⁶²	Glennon K...Brennan D	35379705	2022
44	Clinical, Morphologic, and Molecular Features Associated With Ovarian Metastases From Pattern A Endocervical Adenocarcinomas. ⁶²	Feinberg J...Park KJ	34889854	2022
45	[Prevalence and frequencies of human papilloma virus types in adenocarcinoma in situ of the uterine cervix]. ⁶²	Jin J...Zhou X	35359046	2022
46	A computerized tomography-based radiomic model for assessing the invasiveness of lung adenocarcinoma manifesting as ground-glass opacity nodules. ⁶²	Zhu M...Chen L	35429974	2022
47	Gene expression profiling using targeted RNA-sequencing to elucidate the progression from histologically normal lung tissues to non-invasive lesions in invasive lung adenocarcinoma. ⁶²	Kadonaga T...Umekita Y	35067776	2022
48	Identification and evaluation of circulating small extracellular vesicle microRNAs as diagnostic biomarkers for patients with indeterminate pulmonary nodules. ⁶²	Zheng D...Jiang G	35366907	2022
49	Intrapericardial Thymoma Presented as Pericardial Tamponade with Post-Operative Myasthenia Gravis. ⁶²	Tsai YH...Huang TW	35630026	2022
50	Adenocarcinoma in situ detected on a thin-walled lung cavity: a case report. ⁶²	Sakai T...Iyoda A	35377018	2022

Sources

Genes for Adenocarcinoma in Situ

Genes related to Adenocarcinoma in Situ (0 elite genes):

(show all 22)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	14.26	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
2	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	14.1	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
3	SOX17	SRY-Box Transcription Factor 17	Protein Coding	11.82	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
4	CLDN10	Claudin 10	Protein Coding	11.52	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
5	CLDN1	Claudin 1	Protein Coding	11.21	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
6	U2AF1	U2 Small Nuclear RNA Auxiliary Factor 1	Protein Coding	7.52	DISEASES inferred ¹⁴ ¹⁴
7	INSM1	INSM Transcriptional Repressor 1	Protein Coding	7.1	DISEASES inferred ¹⁴
8	EGFR	Epidermal Growth Factor Receptor	Protein Coding	6.78	DISEASES inferred ¹⁴
9	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	6.46	DISEASES inferred ¹⁴
10	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	6.43	DISEASES inferred ¹⁴
11	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	6.35	DISEASES inferred ¹⁴
12	NKX2-1	NK2 Homeobox 1	Protein Coding	6.32	DISEASES inferred ¹⁴
13	PTPRN	Protein Tyrosine Phosphatase Receptor Type N	Protein Coding	6.25	DISEASES inferred ¹⁴
14	KRT7	Keratin 7	Protein Coding	6.23	DISEASES inferred ¹⁴
15	MUC6	Mucin 6, Oligomeric Mucus/Gel-Forming	Protein Coding	6.19	DISEASES inferred ¹⁴
16	GP5	Glycoprotein V Platelet	Protein Coding	6.17	DISEASES inferred ¹⁴
17	MAPK8IP1	Mitogen-Activated Protein Kinase 8 Interacting Protein 1	Protein Coding	6.13	DISEASES inferred ¹⁴
18	NAPSA	Napsin A Aspartic Peptidase	Protein Coding	6.12	DISEASES inferred ¹⁴
19	PDPN	Podoplanin	Protein Coding	6.09	DISEASES inferred ¹⁴
20	TP53	Tumor Protein P53	Protein Coding	6.05	DISEASES inferred ¹⁴
21	ROS1	ROS Proto-Oncogene 1, Receptor Tyrosine Kinase	Protein Coding	5.93	DISEASES inferred ¹⁴
22	CDX2	Caudal Type Homeobox 2	Protein Coding	5.84	DISEASES inferred ¹⁴

Sources

Variations for Adenocarcinoma in Situ

Sources

Expression for Adenocarcinoma in Situ

Search GEO for disease gene expression data for Adenocarcinoma in Situ.

Sources

Pathways for Adenocarcinoma in Situ

Pathways related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

(show all 22)

#	Super pathways	Score	Top Affiliating Genes
1	Malignant pleural mesothelioma ⁷⁴	12.55	TP53 SOX17 HRAS EGFR CDKN2A
2	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.42	ALK CDKN2A EGFR HRAS KRAS TP53
3	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.34	EGFR HRAS KRAS TP53
4	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.32	TP53 KRAS HRAS EGFR
5	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.29	TP53 KRAS HRAS EGFR
6	MAPK signaling pathway ⁷⁴	12.16	TP53 MAPK8IP1 KRAS HRAS EGFR
7	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.08	TP53 KRAS HRAS EGFR
8	22q11.2 copy number variation syndrome ⁷⁴	11.92	TP53 GP5 EGFR CLDN1
9	Epithelial to mesenchymal transition in colorectal cancer ⁷⁴	11.86	TP53 KRAS HRAS CLDN10 CLDN1
10	Signaling by EGFR ⁶⁶ Show member pathways EGFR downregulation ⁶⁶ GAB1 signalosome ⁶⁶	11.77	KRAS HRAS EGFR
11	mTOR Pathway ⁷⁰ Show member pathways TGF-beta Pathway ⁷⁰	11.64	TP53 KRAS HRAS
12	Gastrin signaling pathway ⁷⁴	11.6	KRAS HRAS EGFR CLDN1 CDKN2A
13	Agrin Interactions at Neuromuscular Junction ⁶⁴	11.48	KRAS HRAS EGFR
14	Vemurafenib Pathway, Pharmacodynamics ⁶⁰	11.33	KRAS HRAS EGFR
15	Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	11.27	KRAS HRAS ALK
16	Head and neck squamous cell carcinoma ⁷⁴	11.22	TP53 KRAS HRAS EGFR CDKN2A
17	Aryl hydrocarbon receptor pathway ⁷⁴	11.13	EGFR HRAS KRAS
18	Transcription_Transcription factor Tubby signaling pathways ²²	11.12	TP53 KRAS HRAS EGFR
19	Extracellular vesicle-mediated signaling in recipient cells ⁷⁴	11.08	KRAS HRAS EGFR
20	Gastrin-CREB signalling pathway via PKC and MAPK ⁶⁶ Show member pathways EGFR Transactivation by Gastrin ⁶⁶	11.04	KRAS HRAS EGFR
21	TNF-alpha signaling pathway ⁷⁴ Show member pathways RAS GTPase cycle mutants ⁶⁶ Signaling by RAS GAP mutants ⁶⁶ Signaling by RAS GTPase mutants ⁶⁶	10.67	KRAS HRAS
22	Bladder cancer ⁷⁴	10.62	TP53 KRAS HRAS EGFR CDKN2A

Sources

GO Terms for Adenocarcinoma in Situ

Biological processes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	9.96	TP53 SOX17 NKX2-1 KRAS HRAS CDKN2A
2	positive regulation of cell migration	GO:0030335	9.65	PDPN INSM1 HRAS EGFR CLDN1
3	Ras protein signal transduction	GO:0007265	9.23	TP53 KRAS HRAS CDKN2A
4	positive regulation of miRNA maturation	GO:1903800	9.16	TP53 EGFR

Sources

Sources for Adenocarcinoma in Situ

¹ BitterDB

² CDC

³ Cell Signaling Technology

⁴ ClinicalTrials

⁵ ClinVar

⁶ CNVD

⁷ Cochrane Library

⁸ Cosmic

⁹ dbSNP

¹⁰ DGIdb

¹¹ Disease Ontology

¹² diseasecard

¹³ DiseaseEnhancer

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ EFO

¹⁷ ExPASy

¹⁸ FMA

¹⁹ GARD

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HMDB

³⁰ HPO

³¹ ICD10

³² ICD10 via Orphanet

³³ ICD11

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ LifeMap

³⁷ LncRNADisease

³⁸ LOVD

³⁹ MalaCards

⁴⁰ MedGen

⁴¹ MedlinePlus

⁴² MedlinePlus Genetics

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NINDS

⁵³ Novoseek

⁵⁴ Novus Biologicals

⁵⁵ ODiseA

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 08-Dec-2022)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubChem

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ WikiPathways

⁷⁵ Wikipedia

MCID: ADN012 MIFTS: 42	Adenocarcinoma in Situ Categories: Cancer diseases, Endocrine diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables